Top 3 Losing Stocks: Integrated Device Technology Inc (IDTI), NewLink Genetics Corp (NLNK), And Infinera Corp. (INFN)

Posted by Ryan Mandell January 7, 2015 0 Comment 1229 views

New York, NY – GDP INSIDER  – 01/07/2014.

Integrated Device Technology Inc (NASDAQ:IDTI) in panicked following a move by Qualcomm. Inc. (NASDAQ:QCOM) to select its rival for wireless charging technology. QCOM is pushing aggressively into wireless charging. In the latest move it chose the design of On Semiconductor Corp (NASDAQ:ONNN) instead of that of Integrated Device, raising the fears that IDTI may have been abandoned.

A research note by a firm known as Dougherty & Co triggered a sell-off  in the sale of Integrated Device Technology Inc (NASDAQ:IDTI). The note mentioned that the move by QCOM implied that Integrated Device had lost the wireless charging business opportunity On Semiconductor. Nonetheless, the firm further stated that IDTI could still win its way back to QCOM. However, some other analysts pointed out that the inclusion of On Semiconductor did not mean that some other vendors had been kicked out.

Is IDTI Going To Turn It Around Or Will It Continue To Freefall? See Where IDTI Is Going Next With A Free Trend Analysis

NewLink Genetics Corp (NASDAQ:NLNK) will have to offer its Ebola vaccine at a lower dose following complaints from volunteers in the trial. The trial of the vaccine had been temporarily suspended following complaints of joint pain among the trial volunteers, said the University of Geneva hospital. The report that NewLink Genetics was moving to lower the dosage of its Ebola vaccine caused panic among investors leading to a sell-off in the stock.

Meanwhile, NewLink Genetics Corp (NASDAQ:NLNK) received $30 million financial backing from the U.S. Department of Health to accelerate the development of its Ebola vaccine.  NewLink Genetics is collaborating with Merck & Co., Inc. (NYSE:MRK) in the development of the vaccine.

Will  NLNK Continue To Drift Lower Or Will It Be Able To Find Support And Reverse? See What’s In Store For NLNK With A Free Trend Report

Infinera Corp. (NASDAQ:INFN) was downgraded at Needham and had its “Conviction Buy” rating removed at Goldman Sachs Group Inc (NYSE:GS). The rating firms did not particularly cite that the company is failing in its business, but stated that the potential upside in its stock price had reduced because of the recent gains. Shares of Infinera have gone through a series of gains, rising from below $9 back in April. Needham cut Infinera Corp. (NASDAQ:INFN) to a “Hold”.

Analysts on the average expect Infinera Corp. (NASDAQ:INFN) to post 13.4% revenue growth in 2015.

Is INFN Going To Continue Selling Off Or Will Things Start Turning Around Soon? See What’s Next For INFN With A Free Trend Report

About UltimateStockAlerts provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment